ETS6103

ETS6103 is a controlled-release formulation of tramadol developed by e-Therapeutics for the once-daily treatment of major depressive disorder (MDD), particularly as a second-line therapy for patients who do not respond to first-line selective serotonin reuptake inhibitor (SSRI) treatments[3][6][10]. Tramadol is a centrally acting synthetic opioid analgesic with additional activity as a serotonin and norepinephrine reuptake inhibitor. The mechanism of action involves agonism at the mu-opioid receptor and inhibition of serotonin uptake[3]. In clinical trials, ETS6103 demonstrated rapid onset antidepressant effects and an improved side effect profile compared to tricyclic antidepressants like amitriptyline[1][6]. However, in phase IIb studies using lower doses than earlier trials, it did not meet its primary endpoint of non-inferiority to amitriptyline in achieving remission but showed some efficacy and better tolerability[6][10].

Brand names

Viotra

Other names

Tramadol controlled releaseTramadol extended release - e-TherapeuticsTramadol hydrochlorideTramadol sustained release - e-Therapeutics